Champions Oncology (CSBR) Depreciation & Amortization (CF) (2010 - 2026)
Champions Oncology (CSBR) posted quarterly Depreciation & Amortization (CF) of $321000.0 for Q2 2026, down 18.53% year-over-year from $394000.0 in Q2 2025, and down 5.87% quarter-over-quarter from $341000.0 in Q1 2026.
Champions Oncology (CSBR) Depreciation & Amortization (CF) (2010 - 2026) Analysis & Trends
Champions Oncology's Depreciation & Amortization (CF) history runs 17 years deep, the most recent figure standing at $321000.0 for Q2 2026.
- In Q2 2026, Depreciation & Amortization (CF) fell 18.53% year-over-year to $321000.0; the TTM figure through Apr 2026 stood at $1.4 million (down 16.04% YoY), while the FY2026 annual figure was $1.4 million, down 16.04% from the prior year.
- Depreciation & Amortization (CF) for Q2 2026 stood at $321000.0, down from $341000.0 in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $583000.0 in Q2 2023, with the low at $321000.0 in Q2 2026.
- The 5-year median for Depreciation & Amortization (CF) is $447000.0 (2023), against an average of $449666.7.
- The sharpest annual moves came in 2022 and 2024: Depreciation & Amortization (CF) surged 87.46% in 2022, then fell 21.61% in 2024.
- Champions Oncology's Depreciation & Amortization (CF) stood at $560000.0 in 2022, then fell by 13.57% to $484000.0 in 2023, then dropped by 17.56% to $399000.0 in 2024, then slipped by 10.53% to $357000.0 in 2025, then retreated by 10.08% to $321000.0 in 2026.
- Business Quant data shows CSBR's Depreciation & Amortization (CF) at $321000.0 in Q2 2026, $341000.0 in Q1 2026, and $357000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 40.52 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 191.83 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Champions Oncology | 68.61 Mn | 68.61 Mn | 7.03 Mn | 321,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 321,000.00 |
| Apr 30, 2026 | 321,000.00 |
| Jan 31, 2026 | 341,000.00 |
| Jan 31, 2026 | 341,000.00 |
| Oct 31, 2025 | 357,000.00 |
| Oct 31, 2025 | 357,000.00 |
| Jul 31, 2025 | 358,000.00 |
| Jul 31, 2025 | 358,000.00 |
| Apr 30, 2025 | 394,000.00 |
| Apr 30, 2025 | 394,000.00 |
| Jan 31, 2025 | 398,000.00 |
| Jan 31, 2025 | 398,000.00 |
| Oct 31, 2024 | 399,000.00 |
| Oct 31, 2024 | 399,000.00 |
| Jul 31, 2024 | 449,000.00 |
| Jul 31, 2024 | 449,000.00 |
| Apr 30, 2024 | 457,000.00 |
| Apr 30, 2024 | 457,000.00 |
| Jan 31, 2024 | 481,000.00 |
| Jan 31, 2024 | 481,000.00 |